Speaking at a public policy conference hosted by the Federation of American Hospitals, Health and Human Services (HHS) Secretary Alex Azar told attendees that the Trump administration is not willing to wait long for the healthcare industry to provide patient-consumers with true price transparency.

“This administration is calling on not just doctors and hospitals, but also drug companies and pharmacies, to become more transparent about pricing and outcomes of their services and products,” he said, in prepared remarks. “If that doesn’t happen, we have plenty of levers to pull that would help drive this change.”

“It will require some degree of federal intervention — perhaps even an uncomfortable degree,” he warned. “This administration and this President are not interested in incremental steps. We are unafraid of disrupting existing arrangements.”

Ensuring price transparency is just one of four priorities topping Azar’s list.

“Giving consumers greater control over health information through interoperable and accessible health information technology,” is also a top concern, he said, as are “using experimental models in Medicare and Medicaid to drive value and quality throughout the entire system, and removing government burdens that impede this value-based transformation.”

Find analysis by Modern Healthcare here.